A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
PART I You should read the following discussion in conjunction with our financial statements as of December 31, 2024, and the notes to such financial statements included elsewhere in this Annual Report on Form 10-K. Monopar Therapeutics Inc. (“Monopar,” the “Company,” “we,” “us,” and “our” and similar terms mean Monopar Therapeutics Inc. and its subsidiaries except where the context otherwise requires) is a clinical-stage biopharma company developing an innovative treatment for Wilson disease and novel radiopharmaceuticals for oncology. Our Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Our radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates, conjugated with different radioisotopes, for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor (“uPAR”).
| Metric | TTM | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | - |
| Net Income | -19M | -8.4M | -11M | -9.1M | -6.3M | -4.2M |
| EPS | $-3.13 | $-2.41 | $-3.01 | $-3.45 | $-2.90 | $-2.25 |
| Free Cash Flow | 0 | -7.9M | -7.2M | -7.3M | -4.7M | -3.0M |
| ROIC | -123.1% | -124.9% | -82.5% | -48.1% | -40.2% | -33.5% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.31 | 0.31 | 0.08 | 0.07 | 0.06 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -22M | -8.8M | -11M | -9.1M | -6.5M | -4.3M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -13.7% | -107.2% | -104.2% | -48.1% | -40.2% | -33.5% |
| Shares Outstanding | 7M | 3M | 3M | 3M | 2M | 2M |
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | |||
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0 | 0 | N/A | N/A | N/A | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -17M | -3.3M | -4.3M | -6.5M | -9.1M | -11M | -8.8M | -22M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -17M | -3.2M | -4.2M | -6.3M | -9.1M | -11M | -8.4M | -19M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||||
| ROIC | N/A | -46.7% | -33.5% | -40.2% | -48.1% | -82.5% | -124.9% | -123.1% |
| ROE | N/A | -46.7% | -33.5% | -40.2% | -48.1% | -104.2% | -107.2% | -13.7% |
| ROA | -166.7% | -44.1% | -31.6% | -37.4% | -44.4% | -79.5% | -81.7% | -13.5% |
| Cash Flow | ||||||||
| Op. Cash Flow | -2.6M | -2.7M | -3.0M | -4.7M | -7.3M | -7.2M | -7.9M | -11M |
| Free Cash Flow | -2.6M | -2.7M | -3.0M | -4.7M | -7.3M | -7.2M | -7.9M | 0 |
| Owner Earnings | -2.9M | -3.2M | -4.0M | -4.7M | -7.3M | -8.9M | -9.8M | -13M |
| CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Maint. CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Growth CapEx | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0 |
| D&A | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 305K | 529K | 1.0M | N/A | N/A | 1.6M | 1.9M | 1.9M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||||
| Net Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -128M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 128M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | N/A | 0.06 | 0.06 | 0.07 | 0.08 | 0.31 | 0.31 | 0.00 |
| Interest Coverage | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | N/A | 6.9M | 13M | 16M | 19M | 10M | 5.6M | 142M |
| Total Assets | 9.9M | 7.3M | 13M | 17M | 21M | 13M | 7.3M | 144M |
| Total Liabilities | N/A | 400K | 724K | 1.2M | 1.6M | 3.1M | 1.8M | 2.6M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -18M | -22M | -26M | -32M | -41M | -52M | -60M | -60M |
| Working Capital | 8.8M | 6.9M | 13M | 16M | 19M | 10M | 5.6M | 5.6M |
| Current Assets | 9.1M | 7.3M | 13M | 17M | 21M | 13M | 7.3M | 7.3M |
| Current Liabilities | 312K | 400K | 724K | 1.2M | 1.6M | 3.1M | 1.8M | 1.8M |
| Per Share Data | ||||||||
| EPS | -9.45 | -1.75 | -2.25 | -2.90 | -3.45 | -3.01 | -2.41 | -3.13 |
| Owner EPS | -1.67 | -1.74 | -2.15 | -2.14 | -2.77 | -2.54 | -2.79 | -1.90 |
| Book Value | N/A | 3.75 | 6.73 | 7.22 | 7.18 | 2.89 | 1.60 | 21.18 |
| Cash Flow/Share | -1.50 | -1.45 | -1.61 | -2.14 | -2.77 | -2.07 | -2.25 | -2.91 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 1.8M | 1.8M | 1.9M | 2.2M | 2.6M | 3.5M | 3.5M | 6.7M |
| Valuation | ||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -18.5 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | 14.7 | 4.4 | 2.3 | 4.0 | 1.2 | 2.7 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | N/A | -1.6% | -6.7% | -16.6% | -18.1% | -118.8% | N/A |
| Market Cap | N/A | N/A | 186M | 70M | 44M | 40M | 6.6M | 387M |
| Avg. Price | N/A | N/A | 109.94 | 40.09 | 28.39 | 12.00 | 6.41 | 57.92 |
| Year-End Price | N/A | N/A | 98.95 | 32.00 | 16.67 | 11.43 | 1.89 | 57.92 |
Monopar Therapeutics passes 0 of 9 quality checks, indicating weak fundamentals.
Monopar Therapeutics (MNPR) has a 5-year average return on invested capital (ROIC) of -65.8%. This is below average and may indicate limited pricing power.
Monopar Therapeutics (MNPR) has a market capitalization of $387M. It is classified as a small-cap stock.
Monopar Therapeutics (MNPR) does not currently pay a regular dividend.
Monopar Therapeutics (MNPR) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Monopar Therapeutics (MNPR) generated $-8 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Monopar Therapeutics (MNPR) has a debt-to-equity ratio of 0.31. This indicates a conservatively financed balance sheet.
Monopar Therapeutics (MNPR) reported earnings per share (EPS) of $-2.41 in its most recent fiscal year.
Monopar Therapeutics (MNPR) has a return on equity (ROE) of -107.2%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 7 years of financial data for Monopar Therapeutics (MNPR), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Monopar Therapeutics (MNPR) has a book value per share of $1.60, based on its most recent annual SEC filing.